These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3389353)

  • 1. Reduction in liver iron in hemodialysis patients with transfusional iron overload by deferoxamine mesylate.
    Mossey RT; Wielopolski L; Bellucci AG; Wilkes BM; Chandra M
    Am J Kidney Dis; 1988 Jul; 12(1):40-4. PubMed ID: 3389353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusional iron overload in patients undergoing dialysis: treatment with erythropoietin and phlebotomy.
    McCarthy JT; Johnson WJ; Nixon DE; Jenson BM; Moyer TP
    J Lab Clin Med; 1989 Aug; 114(2):193-9. PubMed ID: 2754306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload and mobilization in long-term hemodialysis patients.
    Hakim RM; Stivelman JC; Schulman G; Fosburg M; Wolfe L; Imber MJ; Lazarus JM
    Am J Kidney Dis; 1987 Oct; 10(4):293-9. PubMed ID: 3661550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients.
    Jensen PD; Jensen FT; Christensen T; Ellegaard J
    Br J Haematol; 1995 Apr; 89(4):880-9. PubMed ID: 7772526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.
    Andreoli SP; Cohen M
    Kidney Int; 1989 Jun; 35(6):1330-5. PubMed ID: 2770113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the ferritin/alanine aspartate transaminase ratio as an iron overload marker independent of liver cell damage.
    Triadou P; Regnat-Lusinchi A; Girot R
    Eur J Haematol; 1989 Nov; 43(5):423-7. PubMed ID: 2612615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detoxification in hemosiderosis.
    Simon P
    Blood Purif; 1985; 3(1-3):75-88. PubMed ID: 3913449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.
    Inati A; Musallam KM; Wood JC; Taher AT
    Blood; 2010 Apr; 115(14):2980-1; author reply 2981-2. PubMed ID: 20378761
    [No Abstract]   [Full Text] [Related]  

  • 15. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
    Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of iron overload in paediatric patients on chronic haemodialysis.
    Eijgenraam FJ; Donckerwolcke RA; van Dijken PJ
    Pediatr Nephrol; 1988 Jul; 2(3):303-8. PubMed ID: 3153030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum bactericidal activity for Yersinia enterocolitica in hemodialysis patients: effects of iron overload and deferoxamine.
    Gaughan WJ; Beserab A; Stein HD; Sirota RA; Yudis M
    Am J Kidney Dis; 1992 Feb; 19(2):144-8. PubMed ID: 1739096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM; Griffith PM; Nienhuis AW; McLaren CE; Young NS; Tucker EE; Allen CJ; Farrell DE; Harris JW
    N Engl J Med; 1994 Sep; 331(9):567-73. PubMed ID: 8047080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.